{"id":7811,"date":"2026-02-24T06:08:29","date_gmt":"2026-02-24T06:08:29","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/glp-3-retatrutide\/"},"modified":"2026-04-29T08:49:41","modified_gmt":"2026-04-29T15:49:41","slug":"glp-3","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/glp-3\/","title":{"rendered":"GLP-3 \u2014 Published Research"},"content":{"rendered":"<div style=\"max-width:800px;margin:0 auto\">\n<p style=\"color:#a1a1aa;font-size:14px;margin-bottom:30px\"><a href=\"\/es\/producto\/glp-3\/\" style=\"color:#00e5ff\">\u2190 Back to GLP-3 product page<\/a><\/p>\n<section id=\"panda-glp3-research-orientation\" style=\"background:#111827;border-radius:14px;padding:20px 22px;margin:28px 0\">\n<h2 style=\"color:#fafafa;margin:0 0 10px;font-size:24px\">How to read this GLP-3 \/ G3 research page<\/h2>\n<p style=\"color:#a1a1aa;line-height:1.7;margin:0 0 12px\">This page summarizes published GLP-3 \/ LY3437943 literature by experimental theme, including receptor binding, cell-based signaling, glucagon-receptor pathway context, and multi-receptor design. It is a literature map for research documentation, not a protocol or human-use resource.<\/p>\n<ul style=\"color:#a1a1aa;line-height:1.7;margin:0 0 12px 20px\">\n<li><strong style=\"color:#fafafa\">Search terminology:<\/strong> GLP-3, G3 peptide, G3R, G3-R, Triple-G, and LY3437943 may refer to the same research-compound family in catalog and literature searches.<\/li>\n<li><strong style=\"color:#fafafa\">Mechanistic scope:<\/strong> summaries focus on receptor-assay and preclinical research design, not product claims or intended uses.<\/li>\n<li><strong style=\"color:#fafafa\">Documentation links:<\/strong> compare the <a href=\"\/es\/producto\/glp-3\/\" style=\"color:#00e5ff\">GLP-3 catalog listing<\/a>, <a href=\"\/es\/coa\/\" style=\"color:#00e5ff\">COA hub<\/a>, y <a href=\"\/es\/research-framework\/\" style=\"color:#00e5ff\">research framework<\/a>.<\/li>\n<\/ul>\n<p style=\"color:#71717a;font-size:13px;line-height:1.6;margin:0\">Panda Peptides products are for research use only. No dosing, administration, reconstitution, treatment, or human-use guidance is provided.<\/p>\n<\/section>\n<h3 style=\"color:#fafafa;font-size:22px;margin-bottom:8px\">Biblioteca de investigaci\u00f3n<\/h3>\n<p style=\"color:#71717a;font-size:13px;margin-bottom:20px\">Published research on this compound \u2014 for educational purposes only<\/p>\n<details style=\"background:#18181b;border-radius:10px;margin-bottom:12px;overflow:hidden\">\n<summary style=\"padding:18px 24px;color:#00e5ff;font-size:16px;font-weight:600;cursor:pointer\">How does GLP-3 engage three receptor types simultaneously? (for educational purposes only)<\/summary>\n<div style=\"padding:0 24px 20px;color:#a1a1aa;font-size:15px;line-height:1.7\">\n<p>GLP-3 (LY3437943) is a single peptide engineered to activate GIP, GLP-1, and glucagon receptors through distinct structural domains within one alpha-helical chain. The peptide backbone incorporates sequence elements from all three native ligands, with the N-terminal region primarily driving glucagon and GLP-1 receptor activation and mid-chain residues contributing to GIP receptor engagement. A C-20 fatty diacid moiety enables albumin binding for extended half-life. In cell-based assays, GLP-3 demonstrates agonist activity at all three receptors with engineered potency ratios. For laboratory research use only.<\/p>\n<p style=\"font-size:12px;color:#52525b;font-style:italic\">Citation: Coskun T, Urva S, Roell WC, et al. <em>Cell Metab.<\/em> 2022;34(9):1234-1247.e9. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36070752\/\" style=\"color:#71717a\" rel=\"nofollow noopener\" target=\"_blank\">PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<details style=\"background:#18181b;border-radius:10px;margin-bottom:12px;overflow:hidden\">\n<summary style=\"padding:18px 24px;color:#00e5ff;font-size:16px;font-weight:600;cursor:pointer\">What does the glucagon receptor component contribute to GLP-3&#8217;s pharmacology? (for educational purposes only)<\/summary>\n<div style=\"padding:0 24px 20px;color:#a1a1aa;font-size:15px;line-height:1.7\">\n<p>The glucagon receptor (GCGR) agonist component distinguishes GLP-3 from dual GIP\/GLP-1 agonists. Glucagon receptor activation in preclinical models has been associated with increased hepatic lipid oxidation and elevated energy expenditure through thermogenic pathways. In cell-based assays, GLP-3 activates GCGR-mediated cAMP signaling, engaging hepatic metabolic pathways distinct from those activated by GLP-1R or GIPR. The inclusion of GCGR agonism creates a pharmacological profile not achievable with mono- or dual-agonist compounds, engaging liver, pancreas, and adipose tissue receptor populations simultaneously. For laboratory research use only.<\/p>\n<p style=\"font-size:12px;color:#52525b;font-style:italic\">Citation: Coskun T, Urva S, Roell WC, et al. <em>Cell Metab.<\/em> 2022;34(9):1234-1247.e9. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36070752\/\" style=\"color:#71717a\" rel=\"nofollow noopener\" target=\"_blank\">PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<details style=\"background:#18181b;border-radius:10px;margin-bottom:12px;overflow:hidden\">\n<summary style=\"padding:18px 24px;color:#00e5ff;font-size:16px;font-weight:600;cursor:pointer\">How does GLP-3 compare structurally to dual agonists like GLP-2 T? (for educational purposes only)<\/summary>\n<div style=\"padding:0 24px 20px;color:#a1a1aa;font-size:15px;line-height:1.7\">\n<p>While GLP-2 T engages two receptors (GIP and GLP-1), GLP-3&#8217;s peptide sequence was engineered to additionally activate the glucagon receptor \u2014 requiring incorporation of glucagon-derived residues not present in dual agonist designs. Both compounds share lipidation strategies (C-20 fatty diacid for albumin binding) and DPP-4 resistance modifications, but GLP-3&#8217;s sequence diverges substantially to accommodate three-receptor cross-reactivity within a single linear peptide. The structural challenge of maintaining potency at three distinct class B GPCRs simultaneously required extensive sequence optimization. For laboratory research use only.<\/p>\n<p style=\"font-size:12px;color:#52525b;font-style:italic\">Citation: Coskun T, Urva S, Roell WC, et al. <em>Cell Metab.<\/em> 2022;34(9):1234-1247.e9. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36070752\/\" style=\"color:#71717a\" rel=\"nofollow noopener\" target=\"_blank\">PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<details style=\"background:#18181b;border-radius:10px;margin-bottom:12px;overflow:hidden\">\n<summary style=\"padding:18px 24px;color:#00e5ff;font-size:16px;font-weight:600;cursor:pointer\">What is GLP-3&#8217;s receptor potency profile across GIP, GLP-1, and glucagon receptors? (for educational purposes only)<\/summary>\n<div style=\"padding:0 24px 20px;color:#a1a1aa;font-size:15px;line-height:1.7\">\n<p>In vitro characterization demonstrates that GLP-3 activates all three target receptors with distinct potency ratios. The compound shows highest relative potency at the GIP receptor, followed by GLP-1R, with moderate but pharmacologically relevant GCGR agonism. EC\u2085\u2080 values for cAMP accumulation at each receptor have been characterized in HEK293 cells expressing human receptors. The intentional potency imbalance \u2014 strongest at GIPR, intermediate at GLP-1R, and lowest at GCGR \u2014 was engineered to balance the overall receptor activation profile during preclinical characterization. For laboratory research use only.<\/p>\n<p style=\"font-size:12px;color:#52525b;font-style:italic\">Citation: Coskun T, Urva S, Roell WC, et al. <em>Cell Metab.<\/em> 2022;34(9):1234-1247.e9. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36070752\/\" style=\"color:#71717a\" rel=\"nofollow noopener\" target=\"_blank\">PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n<p style=\"color:#a1a1aa;font-size:14px;line-height:1.7;margin:24px 0 0\">To compare published studies with Panda batch documentation, review <a href=\"\/es\/coa\/\" style=\"color:#00e5ff\">Reportes de laboratorio (COAs)<\/a>, <a href=\"\/es\/quality-and-testing\/\" style=\"color:#d946ef\">Calidad y pruebas<\/a>, la <a href=\"\/es\/research-framework\/\" style=\"color:#00e5ff\">gu\u00eda para evaluar materiales de investigaci\u00f3n<\/a>, o nuestras <a href=\"\/es\/faq\/\" style=\"color:#d946ef\">Preguntas frecuentes<\/a>.<\/p>\n<div class=\"panda-research-next-card\" style=\"margin:28px 0 0;padding:20px;background:#111113;border:1px solid #27272a;border-radius:14px;color:#a1a1aa;font-size:14px;line-height:1.65\">\n<h3 style=\"margin:0 0 10px;color:#fafafa;font-size:18px;line-height:1.3\">Continue reviewing GLP-3<\/h3>\n<p style=\"margin:0 0 14px\">Use the research references above alongside Panda\u2019s batch documentation and catalog specifications.<\/p>\n<div style=\"display:flex;flex-wrap:wrap;gap:10px\"><a href=\"\/es\/producto\/glp-3\/\" style=\"display:inline-block;padding:9px 12px;border-radius:999px;background:#18181b;color:#00e5ff;text-decoration:none;border:1px solid #27272a\">View product specs<\/a><a href=\"\/es\/coa\/\" style=\"display:inline-block;padding:9px 12px;border-radius:999px;background:#18181b;color:#00e5ff;text-decoration:none;border:1px solid #27272a\">Check COA library<\/a><a href=\"\/es\/quality-and-testing\/\" style=\"display:inline-block;padding:9px 12px;border-radius:999px;background:#18181b;color:#d946ef;text-decoration:none;border:1px solid #27272a\">Quality &amp; testing<\/a><a href=\"\/es\/research-framework\/\" style=\"display:inline-block;padding:9px 12px;border-radius:999px;background:#18181b;color:#00e5ff;text-decoration:none;border:1px solid #27272a\">Evaluation guide<\/a><a href=\"\/es\/research\/\" style=\"display:inline-block;padding:9px 12px;border-radius:999px;background:#18181b;color:#a1a1aa;text-decoration:none;border:1px solid #27272a\">Research library<\/a><\/div>\n<\/div>\n<div style=\"margin-top:30px;padding:20px;background:#18181b;border-radius:10px;color:#71717a;font-size:13px\">\n<p><strong>Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u2190 Back to GLP-3 product page How to read this GLP-3 \/ G3 research page This page summarizes published GLP-3 \/ LY3437943 literature by experimental theme, including receptor binding, cell-based signaling, glucagon-receptor pathway context, and multi-receptor design. It is a literature map for research documentation, not a protocol or human-use resource. Search terminology: GLP-3, G3 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7811","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7811"}],"version-history":[{"count":5,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7811\/revisions"}],"predecessor-version":[{"id":9492,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7811\/revisions\/9492"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}